Ningbo Menovo Pharmaceutical Co., Ltd. (603538.SS)
CNY 13.35
(0.3%)
CNY 13.35
(0.3%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1.21 Billion CNY | -16.51% |
| 2022 | 1.45 Billion CNY | 15.8% |
| 2021 | 1.25 Billion CNY | 5.4% |
| 2020 | 1.19 Billion CNY | 1.14% |
| 2019 | 1.18 Billion CNY | 39.02% |
| 2018 | 848.96 Million CNY | 40.25% |
| 2017 | 605.32 Million CNY | 4.71% |
| 2016 | 578.08 Million CNY | -3.19% |
| 2015 | 597.16 Million CNY | -6.15% |
| 2014 | 636.3 Million CNY | 26.82% |
| 2013 | 501.72 Million CNY | 3.1% |
| 2012 | 486.64 Million CNY | -0.73% |
| 2011 | 490.24 Million CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q3 | 336.93 Million CNY | -1.13% |
| 2024 Q1 | 262.76 Million CNY | -8.75% |
| 2024 Q2 | 345.11 Million CNY | 31.34% |
| 2023 Q1 | 246.31 Million CNY | 8.85% |
| 2023 Q4 | 287.96 Million CNY | -16.84% |
| 2023 Q3 | 346.27 Million CNY | 3.07% |
| 2023 Q2 | 335.94 Million CNY | 36.39% |
| 2023 FY | 1.21 Billion CNY | -16.51% |
| 2022 Q4 | 226.29 Million CNY | -32.12% |
| 2022 Q3 | 333.37 Million CNY | -16.05% |
| 2022 Q1 | 500.2 Million CNY | 47.36% |
| 2022 Q2 | 397.1 Million CNY | -20.61% |
| 2022 FY | 1.45 Billion CNY | 15.8% |
| 2021 Q4 | 339.44 Million CNY | 49.49% |
| 2021 Q2 | 353.34 Million CNY | 4.45% |
| 2021 Q1 | 338.29 Million CNY | 37.82% |
| 2021 FY | 1.25 Billion CNY | 5.4% |
| 2021 Q3 | 227.07 Million CNY | -35.74% |
| 2020 Q1 | 285.35 Million CNY | -13.21% |
| 2020 Q4 | 245.46 Million CNY | -17.36% |
| 2020 Q3 | 297.02 Million CNY | -18.81% |
| 2020 Q2 | 365.85 Million CNY | 28.21% |
| 2020 FY | 1.19 Billion CNY | 1.14% |
| 2019 FY | 1.18 Billion CNY | 39.02% |
| 2019 Q1 | 254.3 Million CNY | -12.43% |
| 2019 Q2 | 307.03 Million CNY | 20.73% |
| 2019 Q3 | 290.06 Million CNY | -5.53% |
| 2019 Q4 | 328.8 Million CNY | 13.35% |
| 2018 FY | 848.96 Million CNY | 40.25% |
| 2018 Q4 | 290.41 Million CNY | 37.92% |
| 2018 Q3 | 210.56 Million CNY | 8.95% |
| 2018 Q2 | 193.27 Million CNY | 24.93% |
| 2018 Q1 | 154.7 Million CNY | -12.08% |
| 2017 FY | 605.32 Million CNY | 4.71% |
| 2017 Q1 | 145.45 Million CNY | 11.42% |
| 2017 Q4 | 175.96 Million CNY | 39.11% |
| 2017 Q3 | 126.49 Million CNY | -19.64% |
| 2017 Q2 | 157.4 Million CNY | 8.21% |
| 2016 Q1 | 128.43 Million CNY | 0.0% |
| 2016 Q4 | 130.54 Million CNY | -13.06% |
| 2016 Q3 | 150.15 Million CNY | -11.13% |
| 2016 FY | 578.08 Million CNY | -3.19% |
| 2016 Q2 | 168.95 Million CNY | 31.55% |
| 2015 FY | 597.16 Million CNY | -6.15% |
| 2014 Q2 | 136.89 Million CNY | 0.0% |
| 2014 Q1 | 136.89 Million CNY | 0.0% |
| 2014 FY | 636.3 Million CNY | 26.82% |
| 2013 FY | 501.72 Million CNY | 3.1% |
| 2012 FY | 486.64 Million CNY | -0.73% |
| 2011 FY | 490.24 Million CNY | 0.0% |